The role of difluprednate ophthalmic emulsion in clinical practice

References

• AppleDJSolomonKDTetzMRPosterior capsule opacificationSurv Ophthalmol199237731161455302
   PubMed Web of Science ®Google Scholar
• MiyakeKMaekuboKMiyakeYPupillary fibrin membrane; a frequent early complication after posterior chamber lens implantation in JapanOphthalmol19899612281233
   PubMed Web of Science ®Google Scholar
• SchimmerBPParkerKLAdrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormonesHardmanJGLimbirdLEGilmanAGGoodman & Gilman’s The Pharmacological Basis of Therapeutics10th EditionNew YorkMcGraw–Hill200116491677
   Google Scholar
• SandersDRKraffMSteroidal and nonsteroidal anti-inflammatory agents. Effect on postsurgical inflammation and blood–aqueous humor barrier breakdownArch Ophthalmol198410210 145314566385931
   PubMedGoogle Scholar
• KorenfeldMDifluprednate: changing the landscape of ocular pharmacologyExpert Rev Ophthamol200836 619625
   Google Scholar
• BikowskiJThe position not the presence of the halogen in corticosteroids influences potency and side effectsJ Drugs Dermatol200652 12513016485880
   PubMedGoogle Scholar
• YamaguchiMYasuedaSIsowakiAFormulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednateInt J Pharmaceutics2005301121128
   PubMed Web of Science ®Google Scholar
• SweetanaSAkersMJSolubility principles and practices for parenteral drug dosage form developmentJ Pharm Sci Technol199650330342
   Google Scholar
• RajagopalanNDickenCMRavinLJA study of the solubility of amphotericin B in nonaqueous solvent systemsJ Parenter Sci Technol198842971023216269
   PubMedGoogle Scholar
• LoftssonTPetersenDSCyclodextrin solubilization of ETH-615, a zwitterionic drugDrug Dev Ind Pharm1998243653709876597
   PubMed Web of Science ®Google Scholar
• Alvarez-NunezFAYalkowskySHSolubilization of diazepamJ Pharm Sci Technol1998523336
   Google Scholar
• DeickeASuverkrupRDose uniformity and redispersibility of pharmaceutical suspensions. I: quantification and mechanical modeling of human shaking behaviourEur J Pharm Biopharm19994822523210612033
   PubMed Web of Science ®Google Scholar
• DiestelhorstMKwonKASuverkrupRDose uniformity of ophthalmic suspensionsJ Cataract Refract Surg1998246726779610452
   PubMed Web of Science ®Google Scholar
• VandammeTMicroemulsions as ocular drug delivery systems: recent developments and future challengesProg Retin Eye Res200221153411906809
   PubMed Web of Science ®Google Scholar
• KoychaMRochatMHVerainAPhysicochemical stability of emulsions: application to mixtures for parenteral nutritionJ Pharm Belg1988434134243150005
   PubMed Web of Science ®Google Scholar
• TamilvananSBenitaSThe potential of lipid emulsion for ocular drug delivery of lipophilic drugsEur J Pharm Biopharm20045835736815296961
   PubMed Web of Science ®Google Scholar
• FujinoAOhtuSShibataKStudies on the metabolic fate of difluprednate (DFBA). 3. Metabolism in rats and rabbits after subcutaneous administrationPharmacometrics198529713723
   Google Scholar
• TajikaTShirasakiYKimuraMOcular distribution and metabolism after instillation of difluprednate ophthalmic emulsion in rabbits. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)Poster B744, Program 2654. Fort Lauderdale, FL, USA, 6–10 May 2007
   Google Scholar
• YasuedaSKimuraMOhtoriAAnalysis of an anti-inflammatory steroidal drug, difluprednate, in aqueous humor by combination of semi-micro HPLC and column switching methodJ Pharm Biomed Anal2003301735174212485714
   PubMed Web of Science ®Google Scholar
• SakakiHMitoCNemotoSPreclinical toxicity of difluprednate ophthalmic emulsion. The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)Poster B743, Program 2653. Fort Lauderdale, FL, USA, 6–10 May 2007
   Google Scholar
• InoueJYamaguchiMSakakiHPreclinical pharmacokinetics of difluprednate ophthalmic emulsionThe 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B741, Program 2651Fort Lauderdale, FL, USA6–10 May 2007
   Google Scholar
• KidaTTakahaskiHTsuzukiMDifluprednate emulsion inhibits postoperative inflammation in rabbit paracentesis modelThe 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B745, Program 2655Fort Lauderdale, FL, USA6–10 May 2007
   Google Scholar
• OkumuraATsuzukiMWadaTEfficacy of difluprednate ophthalmic emulsion in preclinical studies of uveitisThe 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B742, Program 2652Fort Lauderdale, FL, USA6–10 May 2007
   Google Scholar
• Senju Pharmaceutical Co., Ltd., Osaka, JapanPhase I clinical study of difluprednate: single instillation. Mar 1999. Data on file
   Google Scholar
• Senju Pharmaceutical Co., Ltd., Osaka, JapanPhase I clinical study of difluprednate: repeated instillation31999Data on file
   Google Scholar
• Senju Pharmaceutical Co., Ltd., Osaka, JapanPhase IIa clinical study of difluprednate 0.002% and 0.05% in the treatment of postoperative inflammation22002Data on file
   Google Scholar
• Senju Pharmaceutical Co., Ltd., Osaka, JapanPhase IIb clinical study of difluprednate 0.05% vs betamethasone 0.1% in the treatment of postoperative inflammation42004Data on file
   Google Scholar
• OhjiMTanoYHidaTEfficacy and safety results of a phase III study of difluprednate ophthalmic emulsion 0.05% in postoperative inflammationThe 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B807, Program 3903Fort Lauderdale, FL, USA6–10 May 2007
   Google Scholar
• KorenfeldMSSilversteinSMCookeDLDifluprednate ophthalmic emulsion 0.05% for postoperative inflammation and painJ Cataract Refract Surg200935263419101421
   PubMed Web of Science ®Google Scholar
• OhnoSMochizukiMUsuiMA phase III noninferiority study of difluprednate ophthalmic emulsion 0.05% in the treatment of anterior uveitisThe 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B808, Program 3904Fort Lauderdale, FL, USA6–10 May 2007
   Google Scholar
• MochizukiMOhnoSUsuiMA phase III open-label clinical study of difluprednate ophthalmic emulsion 0.05% in the treatment of severe refractory anterior uveitisThe 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B809, Program 3905Fort Lauderdale, FL, USA6–10 May 2007
   Google Scholar
• Sirion Therapeutics, IncTampaFLA phase III multicenter, randomized, double-masked study of the safety and efficacy of difluprednate 0.05% ophthalmic emulsion compared to prednisolone acetate 1% ophthalmic suspension in the treatment of endogenous anterior uveitis122008Data on file.
   Google Scholar
• ArmalyMFEffect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eyeArch Ophthalmol19637048249114078870
   PubMed Web of Science ®Google Scholar
• ArmalyMFEffect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eyeArch Ophthalmol19637049249914078871
   PubMedGoogle Scholar
• BaudouinCAllergic reaction to topical eyedropsCurr Opin Allergy Clin Immunol2005545946316131924
   PubMed Web of Science ®Google Scholar
• PriceFDo you welcome BAK? Weighing the toxicity riskOptometric Management20043 [accessed 2009 Apr 5]. Available from: http://www.optometric.com/article.aspx?articleZ71020
   Google Scholar
• DartJCorneal toxicity: the epithelium and stroma in iatrogenic and factitious diseaseEye20031788689214631393
   PubMed Web of Science ®Google Scholar
• YeeRWThe effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a reviewCurr Opin Ophthalmol20071813413917301615
   PubMed Web of Science ®Google Scholar
• AbelsonMBWashburnSThe downside of tear preservativesRev Ophthalmol20029102106
   Google Scholar
• NegiAKBrowningACVernonSASingle perioperative triamcinolone injection versus standard postoperative steroid drops after uneventful phacoemulsification surgery: randomized controlled trialJ Cataract Refract Surg2006323 46847416631060
   PubMed Web of Science ®Google Scholar
• DiederichSScholzTEigendorffEPharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenasesHorm Metab Res20043642342915241735
   PubMed Web of Science ®Google Scholar
• DunneJAJacobsNMorrisonAEfficacy in anterior uveitis of two known steroids and topical tolmetinBr J Ophthalmol1985691201253881125
   PubMed Web of Science ®Google Scholar
• Statistics on Blindness and Blinding Diseases in the United States [web page]The University of Washington Department of Ophthalmology; c1997–2004[updated 2004 Jan 1; accessed 2009 Apr 5]. Available from: http://depts.washington.edu/ophthweb/statistics.html
   Google Scholar
• Frequently Asked Questions [web page]American Uveitis Societyc2002 [accessed 2009 Apr 5]. Available at: http://www.uveitissociety.org/pages/faq.html
   Google Scholar
• EisenSAMillerDKWoodwardRSThe effect of prescribed daily dose frequency on patient medication complianceArch Intern Med1990150188118842102668
   PubMed Web of Science ®Google Scholar